

Model Portfolio Report

Scripts with Assigned Weights	Use the command /phrm_20_2260000_e_10 in the Telegram Bot @ShubhaangBot to access the most recent Model Portfolio Composition, including the list of scripts and their respective investment weightages, specific to this subscription plan.	
Bot Command Parameters		
/	Character to recognise the text as a Command in Telegram Bots	Mandatory - Static
phrm	Code specific to the Stocks Group as per the subscription plan	Mandatory - Static
20	Number of scripts needed in the portfolio as per the subscription plan	Mandatory - Static
2260000	Portfolio Investment Value	Mandatory - Dynamic
e	ETFs composition code specific to the subscription plan. 'd' for Debt ETFs, 'e' for Equity ETFs, 'n' for all other scripts.	Optional - Static
10	ETFs composition percentage value specific to the subscription plan.	Optional - Static

Factsheet

Model Portfolio Title	20 Equity and ETF Scripts Long Term Growth Portfolio Industry - Pharmaceuticals Rebalancing Monthly Equity ETFs Composition is 10% 12 Months Subscription Plan
Launch Date	2025-11-23
Portfolio Type	Industry Specific Portfolio
Portfolio Constituents	Equities and ETFs
Asset Class	Multi Asset
Stocks Group	Industry - Pharmaceuticals
Investment in ETFs	Equity ETFs Composition is 10%
Number of Scripts In the Portfolio	20 Scripts {18 Equities and 2 Equity ETFs}
Portfolio Risk	Future Risk may Exceed 55% {Indicating potential risk exposure from a forward-looking perspective, while accounting for additional risk margin to accommodate unforeseen extreme volatile scenarios.}
Optimal Investment Horizon	11 or more years {A higher risk exposure in the portfolio necessitates a longer investment commitment to achieve optimal growth.}
Rebalancing Frequency	Rebalancing Monthly {Monthly rebalancing typically occurs on the first Monday following the 3rd of each month. If this schedule is missed, the rebalancing will be initiated on the subsequent Monday.}
Minimum Investment	Capital above Rs. 2260000
Subscription Fee	Rs. 56500 per annum {Excluding GST}

Investment Objective	Invest in India's leading generic and biotech firms with strong export potential and domestic demand.		
Investment Rationale	Global Leadership in Generic Medicines: India is a major supplier of affordable generics worldwide, with a strong export-driven growth trajectory that offers substantial earning potential. Rising Domestic Healthcare Spending: Increasing healthcare awareness, insurance coverage, and government initiatives drive sustained demand for pharmaceuticals, supporting long-term revenue growth. Innovation and R&D Expansion: Focus on biosimilars, biotech, and advanced formulations enhances profit margins and positions Indian pharma firms for increased global competitiveness and higher returns compared to other sectors or asset classes.		
Investment Methodology	1. The broad universe for securities comprises of listed companies within the NSE 500 Index and all ETFs, which are meticulously filtered qualitatively in accordance with the predefined investment objective and investment rationale. 2. Proprietary algorithms, advanced quantitative models, and technical analysis are applied to systematically identify securities with the highest likelihood of delivering superior returns. 3. These models, extensively validated across various asset classes and time horizons, incorporate customized proprietary indicators of momentum, volume, volatility, and trend, ensuring that portfolio construction is entirely driven by objective data and high-quality signals, free from biases, prejudices, or emotional influence. 4. The selection of securities and their respective weightings within the model portfolio is further optimized based on factors including the target portfolio size, ETF allocation, average daily trading turnover, available investment capital, rebalancing frequency, as well as the number of quantitative and technical criteria met by each security.		
Backtest Results of this Model Portfolio as per my Investment Model {Equities - over the data of last 16 years between 5 th Oct 2009 to 26 th Dec 2025} {ETFs - over the data of last 4 years between 15 th Dec 2021 to 26 th Dec 2025}			
Average Monthly Returns	2.88%	Annualised Returns	40.63%
Maximum Drawdown	26.61%	Annualised Risk	21.12%
Maximum Recovery Period from Downturns	23 months	Sharpe Ratio	1.616
• This information does not represent actual past performance of this model portfolio and should never be used as a basis for comparing the actual performance of other intermediaries. • This information is presented solely as factual data derived from the back-tested results of my quantitative and technical model, intended for educational purposes only. It highlights the model's potential according to the above mentioned methodology and parameters. • This model have employed various assumptions throughout the back-testing process. • It should not be interpreted as an endorsement, advertisement, or prediction of future performance. • This information should not be relied upon for decision-making purpose.			

- Users are strongly encouraged to exercise extreme caution and perform thorough due diligence when utilizing this information.
- **"Back-test results are not indicative of future performance and do not guarantee any future returns."**
- These back-test results have not been verified by PaRRVA {Past Risk and Return Verification Agency} or any other SEBI-recognized agency.
- The impact of periodic portfolio rebalancing and transaction costs has been factored into these back-test results.

Portfolio Actual Past Performance Vs Benchmark Index

In accordance with the SEBI circular SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2025/004 dated 8/Jan/2025 on "Model Portfolio Framework" for Research Analysts

Portfolio Returns {Since Launch Date}	This data shall be disclosed once SEBI-approved PaRRVA becomes operational and has certified the actual past performance of this Model Portfolio. However, upon request, all previous rebalancing changes related to this Model Portfolio can be shared with its subscribers. {From 2025-11-10 to 2026-2-9; Invested for 13 weeks}
Nifty Pharma Index Returns {Benchmark Index}	-1.87% {From 2025-11-10 to 2026-2-9}

Please thoroughly review the Terms and Conditions, Terms of Service, Do's and Don'ts, Risk Disclosures, Standard Disclosures, Disclaimers, Subscription Policy, and Privacy Policy details before proceeding with any subscription plan.



Contact Details:

Name:	M R Sai Praveen (SEBI Registered Equity Research Analyst)
SEBI Registration Number:	INH000023560
BSE Enlistment Number:	6787
Contact Number:	+91 9916631199 (For Calls, SMS & WhatsApp)
Contact Timings:	8:00 AM to 4:00 PM
Email ID:	support@shubhaang.com
Website	https://shubhaang.com
Address:	#12, Sai Northwood Layout, Gantiganahalli, Yelahanka, Bangalore - 560064

Important Links: <https://shubhaang.com/StandardDisclosures.pdf>

1. [About the Portfolio Manager \(Research Analyst\)](#)
2. [Best Features of The Services](#)
3. [Terms and Conditions](#)
4. [Do's and Don'ts for the Clients](#)
5. [Service Disclosure by Research Analyst](#)
6. [How to Subscribe to a Particular Model Portfolio Plan](#)
7. [Risk Disclosure](#)
8. [Payment Options](#)
9. [Privacy Policy](#)
10. [Grievance Redressal and Dispute Resolution](#)



Standard Warning:

- Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
- Registration granted by SEBI and enlistment with BSE in no way guarantee the performance of our services or provide any assurance of returns to investors.
- The information disseminated by M R Sai Praveen via this website, the Telegram Bot @ShubhaangBot and through any of our reports is intended solely for informational and educational purposes. It should not be construed as an solicitation to purchase any of his subscription plans.

Disclaimer:

Investing in securities carries inherent risks, and by engaging with our services, you acknowledge and accept full responsibility for all investment outcomes, including the potential loss of capital. Under no circumstances should decisions be made solely based on the information provided herein. The information and recommendations available on our website and Telegram Bot are for general informational purposes only and do not constitute advice to sell, nor a solicitation to purchase, any securities.

The information and insights contained within the reports are considered to be credible; however, we does not make any warranties regarding their accuracy, completeness, or reliability. Investors are encouraged to independently assess market conditions and associated risks before making any investment decisions.

Neither the research analyst nor any associated personnel attempt to influence or impose their personal views on your stock selection decisions. The research analyst and his associates cannot be held liable for any losses or damages resulting from advice provided through official platforms. No content from the research analyst guarantees or warrants any specific outcome. Despite diligent efforts to ensure accuracy, errors may occur, and caution is advised; the analyst and his associates shall not be liable for any losses incurred.

All information, model portfolio compositions, advice, and content shared across our website, research reports, factsheets, and Telegram Bot are intended for personal use only and must not be reproduced or redistributed in any form without prior consent from M R Sai Praveen.